Cardiovascular disease remains the leading cause of death worldwide, and thrombosis, the formation of blood clots inside blood vessels, sits at the center of heart attacks, strokes, and many other vascular events. While existing anticoagulant and antiplatelet drugs save lives, they carry risks of bleeding and are not always suitable for long-term preventive use. This has fueled intense interest in dietary compounds and botanical extracts that might gently modulate the vascular environment and reduce the likelihood of clots forming in the first place. The new research, led by Jin Tae Kim of the Korea Research Institute of Bioscience and Biotechnology and Hui Mang Son of Chung-Ang University, with corresponding authors Ho Jin Lee of Seoul National University and Hong Jin Lee of Chung-Ang University, adds mangosteen pericarp to the growing list of food-derived candidates worth serious scientific attention.

The research team focused on a 70 percent ethanol extract of the mangosteen pericarp, designated GMPE70, which they selected because it contains a relatively high concentration of α-mangostin, the most studied xanthone in the fruit’s rind. Xanthones are a class of polyphenolic compounds with well-documented antioxidant and anti-inflammatory properties, and α-mangostin in particular has attracted attention for its immunomodulatory effects, its ability to inhibit inflammatory signaling, and its reported benefits in metabolic and cardiovascular contexts. What makes the new study distinctive is that the investigators did not simply test the whole extract or the purified compound in isolation. Instead, they compared GMPE70 directly with α-mangostin at the exact concentration present in the extract, allowing them to determine whether the observed effects could be attributed to α-mangostin alone or whether other constituents of the pericarp contribute.

At the heart of the study lies the endothelium, the thin layer of cells lining the interior surface of blood vessels. A healthy endothelium maintains smooth blood flow, resists unnecessary leukocyte adhesion, and produces nitric oxide, a molecule that keeps vessels relaxed and prevents platelets from sticking together. When the endothelium becomes dysfunctional, often through chronic inflammation, oxidative stress, or metabolic disease, it transforms into a surface that actively promotes clot formation. Inflammatory signaling pathways, most notably the transcription factor nuclear factor kappa B, or NF-κB, switch on genes encoding adhesion molecules such as intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1). These molecules act as molecular Velcro, snagging circulating immune cells and platelets and initiating the cascade that can culminate in an occlusive thrombus.

Using EA.hy926 cells, a widely used human endothelial cell line, the researchers demonstrated that both GMPE70 and α-mangostin at its concentration in the extract suppressed NF-κB activation. This suppression had downstream consequences: the expression of ICAM-1 and VCAM-1, the two key endothelial adhesion molecules, was significantly reduced. Simultaneously, both treatments enhanced the phosphorylation of endothelial nitric oxide synthase (eNOS), the enzyme responsible for producing nitric oxide in blood vessels. Increased eNOS phosphorylation generally means increased NO bioavailability, which promotes vasodilation, inhibits platelet aggregation, and maintains an antithrombotic surface. In other words, the mangosteen compounds appeared to push endothelial cells away from a pro-inflammatory, pro-thrombotic state and back toward a healthy, anticoagulant phenotype.

Perhaps the most visually compelling evidence came from adhesion assays in which the researchers incubated EA.hy926 endothelial cells together with THP-1 monocytes, a human monocytic cell line frequently used to model leukocyte behavior. When endothelial cells are activated, monocytes adhere to their surface, mimicking the early stages of vascular inflammation and thrombus initiation. GMPE70 and α-mangostin both significantly reduced this monocyte-endothelial interaction, confirming that the molecular changes seen at the level of gene and protein expression translated into functional consequences at the cellular level. The team also found that expression of LFA-1, the major leukocyte counter-receptor that binds ICAM-1, was suppressed in the monocytes. This dual effect, reducing both the ligands on the endothelial surface and the receptors on the immune cells, suggests a coordinated dampening of the adhesive dialogue between the two cell types.

To move beyond the Petri dish, the researchers employed a well-established animal model of thrombosis in which rats are injected with collagen and epinephrine. This combination triggers rapid platelet aggregation and widespread vascular occlusion, and it has been used extensively to evaluate the antithrombotic potential of natural products and synthetic compounds alike. When rats received GMPE70 or α-mangostin, the degree of vascular occlusion was significantly attenuated compared to untreated controls. Molecular analysis of vascular tissue revealed that the gene expression of adhesion molecules was regulated by the treatments, mirroring the in vitro findings and suggesting that the mechanisms observed in cultured cells operate in living organisms as well.

The equivalence between the whole extract and purified α-mangostin is one of the study’s most interesting findings. If the effects of GMPE70 could be fully explained by its α-mangostin content alone, this would simplify quality control and standardization for any future nutraceutical or functional food application. It also raises the possibility that α-mangostin serves as the primary pharmacologically active principle of the pericarp with respect to vascular protection, with other xanthones and phenolic compounds playing secondary or synergistic roles that remain to be fully characterized.

The findings align with a broader body of research on α-mangostin. Previous studies have shown that the compound improves endothelial dysfunction in diabetic mouse models by inhibiting the acid sphingomyelinase/ceramide pathway, attenuates blood pressure and reverses vascular remodeling in hypertensive rats by balancing the renin-angiotensin system axes, and induces vasorelaxation through interactions with large-conductance calcium-activated potassium channels. A 2025 systematic review and meta-analysis further documented lipid-lowering effects of α-mangostin in hyperlipidemic animal models. The new study extends this literature by demonstrating, for the first time in a collagen and epinephrine-induced thrombosis model, that both the whole pericarp extract and its principal xanthone can attenuate vascular occlusion and modulate the adhesive program of the vessel wall.

What remains to be determined is whether the doses used in the animal experiments can be translated into realistic human intake levels and whether long-term supplementation with mangosteen pericarp extract would produce meaningful reductions in cardiovascular events. Human clinical trials would need to address questions of bioavailability, since xanthones are known to undergo extensive metabolism, and potential interactions with conventional antithrombotic medications. The authors caution that their work is a foundation rather than a prescription, but they argue that Garcinia mangostana pericarp extract represents a promising candidate for the prevention of thrombosis and the improvement of blood flow.

The research was supported by the National Research Foundation of Korea and by Chung-Ang University Research Scholarship Grants. As interest in food-based approaches to cardiovascular prevention continues to grow, the humble mangosteen, a fruit whose rind has been discarded as waste for centuries, may find itself at the center of a new chapter in vascular health research, one in which the boundary between food and medicine becomes increasingly productive.

Lipoprotein (a), a genetically determined subtype of low-density lipoprotein (LDL), has recently garnered attention due to its association with cardiovascular diseases. Its unique structure, combined with high levels found in some individuals, raises questions about its role in thrombotic events linked to prosthetic valves. The study’s findings suggest that elevated lipoprotein (a) levels are correlated with an increased risk of thrombosis in individuals with these devices, pointing to an urgent need for further investigations into preventative strategies for at-risk patients.

Thrombosis on prosthetic heart valves stems from a complex interplay of factors, including blood flow dynamics, surface properties of the valve, and the body’s response to foreign materials. Artificial heart valves are commonly made of biocompatible materials designed to minimize clot formation. However, the introduction of any device into the bloodstream can trigger a cascade of reactions, making the study of lipoprotein (a) particularly relevant. Elevated levels of this lipoprotein can exacerbate these reactions, resulting in a heightened thrombotic risk.

Patients undergoing heart valve replacement procedures often rely on anticoagulation therapy to mitigate the risk of clot formation. However, the presence of lipoprotein (a) may require a reevaluation of current treatment approaches. Understanding the relationship between lipoprotein (a) levels and prosthetic valve thrombosis could lead to tailored therapeutic strategies that consider individual lipid profiles. This personalized approach could enhance patient outcomes and reduce the incidence of complications.

Moreover, the implications of this research extend beyond just immediate post-operative care. The long-term management of patients with prosthetic valves could be revolutionized by incorporating lipoprotein (a) measurements into routine clinical assessments. As healthcare providers strive to offer the best outcomes, the identification of lipoprotein (a) as a significant risk factor could reshape guidelines for monitoring and treating patients with such heart conditions.

The study emphasizes the importance of ongoing research initiatives aimed at uncovering the mechanistic pathways through which lipoprotein (a) influences thrombosis. Researchers are keen to explore whether modifying lipid levels or pharmacological interventions targeting lipoprotein (a) could decrease the risk of valve-related complications. These advancements may be paving the way for innovative therapies that could minimize thrombotic events and prolong the longevity of artificial heart valves.

In addition to clinical implications, public awareness regarding lipoprotein (a) is paramount. Many individuals remain unaware of their lipoprotein (a) levels, as routine screenings for this lipid component are not typically conducted. The findings of this research could serve as a catalyst for increased screening and education surrounding this crucial biomarker, particularly among high-risk populations. Raising awareness could empower individuals to seek preventative care and early interventions, ultimately improving patient outcomes.

As healthcare systems grapple with the growing burden of cardiovascular diseases, the integration of novel biomarkers such as lipoprotein (a) into existing frameworks may enhance risk stratification. Physicians could be equipped with more robust tools for decision-making, ensuring that patients receive the most suitable interventions tailored to their unique profiles. This holistic approach can improve survival rates and quality of life for patients with prosthetic heart valves.

The authors stress that while these findings may open new avenues for treatment, caution must be exercised. Further longitudinal studies and randomized controlled trials are necessary to solidify the relationship between elevated lipoprotein (a) and thrombosis. Establishing causality will require rigorous investigation and interdisciplinary collaboration to unravel the complexities of this association.

Additionally, the research highlights the need for a multifaceted approach to cardiovascular health. As factors such as genetics, lifestyle, and underlying medical conditions contribute to the risk of thrombosis, understanding how lipoprotein (a) intertwines with these elements could inform more precise therapeutic targets. Cardiologists and primary care physicians together can foster a preventive healthcare model that bases interventions not solely on existing conditions but also on potential risk factors.

In conclusion, the research by Yesin and colleagues presents a significant leap in understanding the nuances of prosthetic heart valve thrombosis through the lens of lipoprotein (a). Their findings illuminate a novel risk factor that warrants attention and invites further exploration. As the medical community acknowledges the implications of this research, it propels the need for continued inquiry into innovative strategies for combating thrombotic complications, ultimately aiming to enhance patient quality of life and reduce adverse outcomes for individuals with prosthetic heart valves.

In a world where cardiovascular diseases remain a leading cause of morbidity and mortality, the implications of these findings reach far beyond the confines of academia. They resonate with individuals, healthcare providers, and policymakers alike. Only by continuing to explore these connections can we hope to pave the way toward safer, more efficient healthcare practices that benefit those suffering from chronic heart conditions.

Subject of Research: The relationship between lipoprotein (a) levels and the risk of prosthetic heart valve thrombosis.

Article Title: Lipoprotein (a) as a risk factor for prosthetic heart valve thrombosis.

Article References: Yesin, M., Kalçık, M., Bayam, E. et al. Lipoprotein (a) as a risk factor for prosthetic heart valve thrombosis. J Artif Organs 29, 7 (2026). https://doi.org/10.1007/s10047-025-01535-6

Image Credits: AI Generated

DOI: https://doi.org/10.1007/s10047-025-01535-6

Keywords: lipoprotein (a), prosthetic heart valves, thrombosis, cardiovascular disease, anticoagulation therapy, personalized medicine, health awareness.

Thrombosis, the pathological formation of blood clots within blood vessels, often leads to severe health crises such as heart attacks, strokes, and pulmonary embolisms. Current therapeutic approaches predominantly include the use of anticoagulant drugs, which, despite their efficacy, carry significant risks like bleeding complications. The burgeoning interest in identifying safer, naturally derived agents has steered scientific inquiry towards plant-based bioactive compounds. The study at hand embarks on an in-depth exploration of onion peel extract, delving into its capacity to mitigate thrombotic responses induced by potent agonists such as collagen and epinephrine in rat models.

The onion peel is an abundant byproduct typically discarded during vegetable preparation, yet it is known to harbor a concentrated array of flavonoids, phenolic compounds, and antioxidants. These compounds have been implicated in various health benefits, including anti-inflammatory and anti-cancer effects. However, their direct role in modulating thrombotic mechanisms has remained inadequately explored until now. The research team employed rigorous experimental protocols to ascertain whether onion peel extract could influence platelet aggregation, coagulation parameters, and thrombus formation under induced pathological conditions.

Intriguingly, the study utilized established thrombosis induction models in rats by administering collagen and epinephrine, which are known to synergistically provoke platelet activation and clot formation. The administration of onion peel extract prior to thrombosis induction resulted in significant attenuation of thrombus weight and size, signaling robust anti-thrombotic activity. These findings not only highlight the therapeutic potential of onion byproducts but also underscore the multifaceted nature of phytochemicals in regulating complex physiological pathways.

Biochemically, the anti-thrombotic effect is postulated to arise from the interference with platelet aggregation and modulation of coagulation cascades. Flavonoids, especially quercetin—abundant in onion peel—are documented inhibitors of platelet activation and are capable of scavenging reactive oxygen species, which contribute to endothelial dysfunction and thrombogenesis. By restoring the oxidative balance and inhibiting key enzymes involved in clot formation, the onion peel extract exerts a comprehensive protective effect against thrombus formation.

Another layer of complexity addressed by the study includes the impact of onion peel on epinephrine-induced thrombosis. Epinephrine, a catecholamine released during stress responses, can exacerbate thrombotic risk by promoting platelet hyperactivity and vasoconstriction. The ability of the onion peel extract to counteract these epinephrine-mediated effects speaks to a potentially valuable role in managing stress-related thrombotic episodes, a condition not adequately controlled by conventional therapies.

Beyond the direct vascular effects, the research also examined coagulation times such as prothrombin time (PT) and activated partial thromboplastin time (aPTT), which are critical indices of the blood’s clotting capability. The onion peel extract prolonged these coagulation parameters, suggesting an inhibitory influence on the intrinsic and extrinsic coagulation pathways. This holistic approach confirms that onion peel acts through multiple mechanisms, making it a compelling candidate for integration into preventive or adjunctive therapeutic strategies.

The implications of these findings reach far beyond the realm of laboratory research. The accessibility and affordability of onion peel, often deemed as waste, open a new avenue for cost-effective cardiovascular disease management, especially in low-resource settings. Moreover, the environmental benefit of repurposing agricultural byproducts aligns with sustainable health and food security goals, adding another layer of appeal to the discovery.

However, the translation from preclinical models to human application remains a challenge. The metabolic pathways and bioavailability of onion peel phytochemicals in humans require thorough investigation, as does the safety profile over extended periods. The researchers advocate for controlled clinical trials to validate efficacy, optimal dosages, and potential interactions with established medications. Such trials could potentially revolutionize dietary recommendations and supplement formulations targeting thrombosis prevention.

The broader scientific community has welcomed these findings with enthusiasm, noting the study’s contribution to the growing body of evidence supporting the medicinal value of functional foods. It reiterates the importance of exploring traditional dietary components through the lens of modern biomedical research, thus bridging ethnobotanical knowledge with cutting-edge science. This synergy promises to usher in a new era where everyday foods can double as prophylactic agents against severe chronic diseases.

Importantly, this research underscores the paradigm shift in pharmaceutical development, which increasingly favors multi-target natural compounds over singular synthetic drugs. The complex phytochemical matrix in onion peel may orchestrate a balanced modulation of blood homeostasis, minimizing adverse effects commonly observed in conventional anticoagulants. This property enhances patient compliance and broadens the therapeutic index, making natural extracts a viable alternative or complement to existing therapies.

In parallel, the incorporation of onion peel extract into nutraceuticals or functional beverages may pave the way for innovative products geared toward cardiovascular health. The food industry stands at the cusp of harnessing such functional ingredients not only for health promotion but also for personalized nutrition strategies tailored to thrombotic risk profiles. These developments highlight the interconnectedness of food science, pharmacology, and clinical medicine in advancing public health.

As the global burden of thrombotic diseases escalates with aging populations and lifestyle changes, the need for novel preventive interventions is more pressing than ever. The study offers a promising outlook, suggesting that a simple, natural compound derived from a common vegetable waste could mitigate life-threatening events associated with blood clots. This encourages a reevaluation of dietary choices and supports investment in further research examining the molecular mechanisms underpinning these protective effects.

Furthermore, the use of advanced analytical techniques to characterize the phytochemical composition of onion peel enhances reproducibility and standardization—a critical factor in moving from bench to bedside. By identifying active constituents and their pharmacodynamics, researchers can optimize extraction processes and dosage forms, ultimately facilitating regulatory approval and clinical adoption. This scientific rigor sets a precedent for similar studies on other plant-derived materials often overlooked in conventional research paradigms.

The exciting prospect of transforming an everyday culinary waste into a medically valuable substance embodies the innovative spirit that drives modern biomedical science. It champions a circular economy in agriculture and healthcare, fostering environmental sustainability alongside human wellness. This integrative approach exemplifies how multidisciplinary collaboration can yield solutions with far-reaching impacts on health outcomes worldwide.

In conclusion, the newly unveiled anti-thrombotic properties of Allium cepa L. peel represent a significant stride toward harnessing nature’s potential in combatting thrombotic disorders. While ecological and economic benefits abound, the scientific validation and clinical translation of these findings remain imperative. Should future studies corroborate these initial promising results, the onion peel might well become a cornerstone in both preventive nutrition and therapeutic regimens aiming to diminish the toll of cardiovascular diseases globally.

Subject of Research:
The anti-thrombotic potential of Allium cepa L. (onion) peel against collagen and epinephrine-induced thrombosis in rat models.

Article Title:
Allium cepa L. (onion) peel alleviates collagen and epinephrine-induced thrombosis in rats.

Article References:
Nam, H.I., Fauziah, A.N., Kim, H. et al. Allium cepa L. (onion) peel alleviates collagen and epinephrine-induced thrombosis in rats. Food Sci Biotechnol (2025). https://doi.org/10.1007/s10068-025-01945-5

Image Credits:
AI Generated

DOI:
https://doi.org/10.1007/s10068-025-01945-5